Theranexus Société Anonyme (EPA:ALTHX)

France flag France · Delayed Price · Currency is EUR
0.7640
-0.0080 (-1.04%)
Jun 20, 2025, 5:35 PM CET
-17.85%
Market Cap 6.52M
Revenue (ttm) 2.28M
Net Income (ttm) -1.77M
Shares Out 8.54M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE 15.63
Dividend n/a
Ex-Dividend Date n/a
Volume 13,454
Average Volume 61,768
Open 0.7720
Previous Close 0.7720
Day's Range 0.7640 - 0.7880
52-Week Range 0.2605 - 1.6800
Beta 1.95
RSI 41.26
Earnings Date Sep 25, 2025

About EPA:ALTHX

Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 10
Stock Exchange Euronext Paris
Ticker Symbol ALTHX
Full Company Profile

Financial Performance

In 2024, EPA:ALTHX's revenue was 2.28 million, an increase of 670.55% compared to the previous year's 296,331. Losses were -1.77 million, -74.15% less than in 2023.

Financial Statements

News

There is no news available yet.